The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.
 
Jeong A Kim
No Relationships to Disclose
 
Uwe Hahn
Honoraria - AstraZeneca
 
Won-Seog Kim
No Relationships to Disclose
 
Isabelle Fleury
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Celgene; Gilead Sciences; Incyte; Janssen; Merck; Novartis; Roche; Seagen
Speakers' Bureau - Abbvie; BeiGene; Gilead Sciences; Incyte; Seagen
 
Kamel Laribi
Leadership - Abbvie; AstraZeneca; BeiGene; Novartis; Takeda
Honoraria - Abbvie; BeiGene; Bristol-Myers Squibb; Janssen; Takeda
Consulting or Advisory Role - BeiGene
Research Funding - Abbvie; BeiGene; Novartis
 
Juan Miguel Bergua Burgues
Stock and Other Ownership Interests - Genomic Health; Roche Pharma AG
Consulting or Advisory Role - CEPLENE; Daiichi Sankyo
Speakers' Bureau - Jazz Pharmaceuticals; Roche/Genentech (Inst)
Research Funding - DAIHI (Inst)
Travel, Accommodations, Expenses - Abbvie; Roche Pharma AG; Roche/Genentech; Sandoz
 
Krimo Bouabdallah
Honoraria - Abbvie; BeiGene; Kite/Gilead; Roche; Sandoz-Novartis; Takeda Science Foundation
Consulting or Advisory Role - BeiGene; Kite/Gilead; Roche; Takeda
Travel, Accommodations, Expenses - BeiGene; Kite/Gilead; Roche; Takeda
 
Nick Forward
Honoraria - AstraZeneca; BeiGene; Roche; Seattle Genetics/Astellas
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; IMV; Incyte; Janssen; Kite/Gilead; Novartis; Pfizer; Roche; Seattle Genetics/Astellas; Servier
Research Funding - ADC Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); IMV (Inst); Merck (Inst); MorphoSys (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - ApoPharma
 
Fontanet Bijou
No Relationships to Disclose
 
David MacDonald
No Relationships to Disclose
 
Craig Anthony Portell
Consulting or Advisory Role - Abbvie; Aptitude Health; AstraZeneca; BeiGene; Carden Jennings; Curio Science; Janssen; Merck; Targeted Oncology
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Kite, a Gilead company (Inst); Loxo/Lilly (Inst); Merck (Inst); Prelude Therapeutics (Inst); Seagen (Inst); TG Therapeutics (Inst); VelosBio (Inst); Xencor (Inst)
 
Hervé Ghesquieres
Honoraria - Abbvie; Gilead Sciences; Roche
Consulting or Advisory Role - Gilead Sciences; Roche
Travel, Accommodations, Expenses - Abbvie; Pierre Fabre
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Bantam Pharmaceutical; Celgene (Inst); Debiopharm Group; Genentech (Inst); Karyopharm Therapeutics; Kite/Gilead; kymera; MorphoSys (Inst); Ryvu Therapeutics; Selvita; TG Therapeutics
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Christopher A. Yasenchak
Stock and Other Ownership Interests - Karyopharm Therapeutics (I)
Consulting or Advisory Role - SeaGen
Speakers' Bureau - BeiGene; Lilly
Research Funding - Seagen
 
Evelyn Rustia
Employment - Gilead Sciences; Pfizer; Seagen
Stock and Other Ownership Interests - Gilead Sciences; Seagen
 
Michelle Fanale
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Pfizer; Seagen
 
Fei Jie
Employment - Seagen
 
Nancy L. Bartlett
Consulting or Advisory Role - Foresight Diagnostics; Genmab/AbbVie (Inst); Kite, a Gilead company; Roche/Genentech
Research Funding - ADC Therapeutics (Inst); Autolus (Inst); Bristol-Myers Squibb/Celgene; Forty Seven (Inst); Janssen (Inst); Kite, a Gilead company; Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Seagen (Inst)